Fig. 2
From: Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells
Responses in LRCC and NLRCC differ following exposure to gemcitabine. a LRCC resistance as measured by cell proliferation assay (normalized to vehicle-treated cells (VTC) after treatment with gemcitabine (GI50) for two doubling times in MiaPaCa2, Panc-1, and Nor-P1 cells (*p < 0.05, **p < 0.01, ***p < 0.001; paired t-test). b Activated caspase 3/7 assay measures reduced apoptosis in LRCC population upon exposure to gemcitabine compared to NLRCC